Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

C. Eng, T.W. Kim, J. Bendell, G. Argilés, N.C. Tebbutt, M. Di Bartolomeo, A. Falcone, M. Fakih, M. Kozloff, N.H. Segal, A. Sobrero, Y. Yan, I. Chang, A. Uyei, L. Roberts, F. Ciardiello, J.B. Ahn, J. Asselah, S. Badarinath, S. BaijalS. Begbie, S. Berry, J.L. Canon, R.G. Carbone, A. Cervantes, Y.J. Cha, K. Chang, A. Chaudhry, E. Chmielowska, S.H. Cho, D. Chu, F. Couture, J. Cultrera, D. Cunningham, E. Van Cutsem, P.J. Cuyle, J. Davies, S. Dowden, M. Dvorkin, V. Ganju, R.V. Garcia, R. Kerr, T.Y. Kim, K. King, J. Kortmansky, K.O. Lam, J. Lee, A.S. Lee, B. Lesperance, E. Maiello

Research output: Contribution to journalArticlepeer-review

Cite this